1. Home
  2. AITR vs TLSA Comparison

AITR vs TLSA Comparison

Compare AITR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AITR
  • TLSA
  • Stock Information
  • Founded
  • AITR 2022
  • TLSA 2013
  • Country
  • AITR United States
  • TLSA United Kingdom
  • Employees
  • AITR N/A
  • TLSA N/A
  • Industry
  • AITR
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • AITR
  • TLSA Health Care
  • Exchange
  • AITR Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • AITR 82.6M
  • TLSA 87.8M
  • IPO Year
  • AITR 2023
  • TLSA 2000
  • Fundamental
  • Price
  • AITR $10.54
  • TLSA $1.19
  • Analyst Decision
  • AITR
  • TLSA
  • Analyst Count
  • AITR 0
  • TLSA 0
  • Target Price
  • AITR N/A
  • TLSA N/A
  • AVG Volume (30 Days)
  • AITR 71.3K
  • TLSA 145.8K
  • Earning Date
  • AITR 01-01-0001
  • TLSA 05-10-2024
  • Dividend Yield
  • AITR N/A
  • TLSA N/A
  • EPS Growth
  • AITR N/A
  • TLSA N/A
  • EPS
  • AITR N/A
  • TLSA N/A
  • Revenue
  • AITR N/A
  • TLSA N/A
  • Revenue This Year
  • AITR N/A
  • TLSA N/A
  • Revenue Next Year
  • AITR N/A
  • TLSA N/A
  • P/E Ratio
  • AITR N/A
  • TLSA N/A
  • Revenue Growth
  • AITR N/A
  • TLSA N/A
  • 52 Week Low
  • AITR $10.11
  • TLSA $0.41
  • 52 Week High
  • AITR $10.57
  • TLSA $1.74
  • Technical
  • Relative Strength Index (RSI)
  • AITR 78.43
  • TLSA 65.44
  • Support Level
  • AITR $10.51
  • TLSA $0.83
  • Resistance Level
  • AITR $10.57
  • TLSA $0.92
  • Average True Range (ATR)
  • AITR 0.01
  • TLSA 0.09
  • MACD
  • AITR -0.00
  • TLSA 0.03
  • Stochastic Oscillator
  • AITR 83.33
  • TLSA 84.52

About AITR AI TRANSPORTATION ACQUISITION CORP Ordinary shares

AI Transportation Acquisition Corp is a blank check company.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: